Daniel Culver, DO
Pulmonary Disease · Cleveland, OHNPI 1154385516
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,078 of the $67,954 with a category attached, or 64.9%. Boehringer Ingelheim accounts for 60.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $20,722 and has fallen 80.6% since, to $4,029 in 2025. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $781.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$41K
- Merck$8K
- Genentech USA, Inc.$6K
- Boehringer Ingelheim International GmbH$6K
- United Therapeutics Corporation$4K
- Bristol Myers Squibb$3K
- plus $142 from 2 others
Across 18 payments — averaging $21,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Enterprises LLC$150K
- Boehringer Ingelheim$93K
- Biogen$57K
- Mallinckrodt Hospital Products Inc.$51K
- Novartis$37K
What the payments were for
- Consulting fees$44,07865%
- Speaking & faculty fees$18,46727%
- Travel & lodging$3,7165%
- Food & beverage$1,6932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 59 | $41,415 |
| Merck | 10 | $7,989 |
| Genentech USA, Inc. | 6 | $6,170 |
| Boehringer Ingelheim International GmbH | 6 | $5,612 |
| United Therapeutics Corporation | 1 | $3,800 |
| Bristol Myers Squibb | 2 | $2,826 |
| Mallinckrodt Enterprises LLC | 2 | $118 |
| Biogen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,954 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Cleveland
- Kristin HighlandCleveland$551K
- Joseph CiceniaCleveland$350K
- Michael MachuzakCleveland$286K
- Marie BudevCleveland$159K
- Leslie TolleCleveland$136K
- Elliott DasenbrookCleveland$114K
- James StollerCleveland$101K
- Gustavo Heresi DavilaCleveland$98K
- Bryan BennCleveland$96K
- Thomas GildeaCleveland$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.